TY - JOUR
T1 - Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
AU - Hasan, Gulam Mustafa
AU - Hassan, Md Imtaiyaz
AU - Sohal, Sukhwinder Singh
AU - Shamsi, Anas
AU - Alam, Manzar
N1 - Publisher Copyright:
© 2023 The Authors. Published by American Chemical Society
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
AB - Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85166764117&partnerID=8YFLogxK
U2 - 10.1021/acsomega.3c02424
DO - 10.1021/acsomega.3c02424
M3 - Review article
AN - SCOPUS:85166764117
SN - 2470-1343
VL - 8
SP - 26685
EP - 26698
JO - ACS Omega
JF - ACS Omega
IS - 30
ER -
